



June 15, 2018

Dear Provider:

This letter is to reaffirm that individuals who are appropriate for admission to any OASAS certified program who are on Medication Assisted Treatment (MAT), including: methadone, buprenorphine, or Vivitrol are eligible for admission to all OASAS certified programs.

Programs must have agreements with an Opioid Treatment Program for the continuation of methadone and with a provider within the residence or through agreement with a prescriber in the community to ensure continuity of buprenorphine or Vivitrol. No program should identify a number of beds or slots for people who are being treated with MAT as this could be considered an additional admission criteria which is not required by regulation and inconsistent with patient rights requirements found in 14 NYCRR Part 815.4(i); all beds or slots should be available for individuals regardless of whether or not they are on MAT.

This directive is consistent with OASAS regulations for program operation (819.2 (c) (d) 822.8 (2) (viii) 820.7 (2)). It is also consistent with SAMHSA TIP 63 which can be found at the following link: <https://www.store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Executive-Summary/SMA18-5063EXSUMM> and also with the OASAS clinical standards found at the following link: https://www.oasas.ny.gov/ManCare/documents/ClinicalStandards_FINAL.pdf.

MAT is the standard of care for opioid use disorder. OASAS expects that programs offer treatment services that align with the current standard of addiction treatment.

Thank you for all that you do to help people recover from substance use disorder. Please email any questions you may have regarding this letter to PICM@oasas.ny.gov or Robert.Kent@oasas.ny.gov.

Sincerely,

Robert A. Kent
General Counsel